Medicine Instructions in Hindi: Clear Directions for Indian Patients
Prepare Hindi medicine directions with a bilingual meaning checklist, source-version tracking and a worked patient-understanding handover.
A topical prescription should connect each exact product to its intended body area, amount, frequency and end or review plan. Explain any measuring method, including fingertip units, using the relevant product and patient context. “Apply locally” is incomplete when several sites or tubes are involved, and a cream’s percentage cannot be used to rank the potency of different corticosteroids.
Indian dermatology and general clinics preparing understandable cream, ointment and lotion instructions for patients or caregivers.
A patient may leave with an emollient, a topical corticosteroid and another treatment for a different area. If every line says “local application”, the patient must reconstruct the plan from memory. Write the exact product and formulation, then name the body area and side when relevant. Keep any area exclusions attached to that particular instruction.
Use words the patient can locate on their own body. “Affected area” may be adequate for one clearly discussed patch but ambiguous when there are several different lesions. If a diagram is used, make its labels correspond to the written medicine names. A colour-only key may fail on a monochrome printout.
Do not infer that every new rash should receive the medicine previously prescribed for another site. MHRA topical-steroid guidance explains that body area matters and that the percentage printed on one corticosteroid does not establish its potency relative to another. The clinical decision belongs to the prescriber, not to the tube’s apparent numerical strength.
Source: MHRA: Topical corticosteroids and withdrawal reactions
A fingertip unit, or FTU, is a practical way of describing an amount of topical preparation. HealthHub describes the conventional measure as a strip from a standard 5 mm nozzle along an adult index finger from the tip to the first crease. This definition explains the measure; it does not determine how many units a particular patient or body area needs.
If the clinician uses FTUs in the plan, show the measuring method and specify the amount for the actual site. An instruction saying “use one FTU” without naming the site, product and frequency is still incomplete. Do not assume a child’s fingertip, a pump, a sachet and every tube opening give an equivalent amount.
Where another method is more appropriate, document it clearly. The aim is a reproducible patient action, not compulsory use of one unit. A demonstration can reveal whether the patient understands the quantity better than a generic “thin layer” phrase, but it should follow the approved clinical instructions.
Cream, ointment and lotion are not merely alternative spellings of the same item. NHS hydrocortisone information explicitly directs patients to follow instructions for their formulation and purpose. When a pharmacy proposes another presentation, have the change reviewed rather than copying the old application wording automatically.
Write the frequency and the intended end or review condition for each product. A fixed course, an intermittent plan and a review-dependent decision should not be printed as though they were identical. This guide supplies no universal steroid duration or reduction schedule.
If two products are to be used on the same area, record the clinician-approved order and spacing where applicable. Do not turn one product leaflet’s interval into a rule for all creams. Advice about washing, coverings, sun exposure or other skin products likewise needs to match the treatment actually selected.
This original map is an organisational tool. Its cells must be completed from the clinical plan, not from example values. It is especially useful when the caregiver reading the prescription is different from the person who attended the consultation.
On a narrow screen, scroll the table horizontally to read all columns.
| Field | What to make explicit | Ambiguity it resolves |
|---|---|---|
| Product and formulation | Verified name, strength and cream/ointment/lotion or other presentation | Similar tubes or a pharmacy replacement |
| Body area and side | Specific site and any relevant exclusions | Using one site’s medicine on another problem |
| Amount and method | Clinician-selected quantity and how it is measured or demonstrated | A unit that has never been explained |
| Frequency | The actual planned application pattern | Copying the first product’s frequency to every row |
| Other products at that site | Reviewed sequence or separation when needed | Two individually clear rows that conflict when combined |
| End or review condition | Date, course or explicit clinical reassessment instruction | Continuing indefinitely because a tube remains |
| Patient demonstration | What the patient or caregiver could identify and explain | Treating a leaflet handover as proof of understanding |
Ask the patient to match each product to its site and explain the amount and timing using the written plan. If the actual tubes are available, confirm the names and formulations. Where only a prescription is present, the clinic can still explain the plan but should not claim to have verified a later pharmacy supply.
Use the patient’s preferred spoken and written language. “Steroid cream”, “itch cream” and “night cream” are weak identifiers when more than one product fits the description. Preserve the verified name on the instruction so the patient and pharmacist can match it after leaving the clinic.
If a caregiver will apply treatment, establish which parts they will assist with and how the patient wants sensitive body-site information handled. Photographs or body diagrams used as clinical evidence need the clinic’s appropriate consent and privacy process; they should not be copied into routine appointment messages.
Fictional patient T-18 attends a Nagpur clinic with an application plan for the left forearm and right shin. The training record uses three invented product identifiers: E cream, S ointment and X cream. E appears at both sites; S appears only at the left forearm and X only at the right shin. These letters identify demonstration rows, not real medicines, ingredients or suitable treatments for those areas.
There are three products, two named sites and four product-to-site relationships. That last count matters. An application editor that allows only one site per medicine may lose E’s second instruction; an editor that automatically copies every direction across sites may erase a deliberate difference. Each relationship needs its own reviewed amount, timing and end or review condition from the actual prescription. This case tests the mapping rather than providing those treatment instructions.
At the 28 October review, the doctor changes the end/review condition for S at the left forearm. The other three relationships remain as recorded in the signed plan. A replacement summary should show the entire current map and identify the changed row. Printing only S would leave the patient to decide whether E and X had stopped; repeating S’s new condition on every row would create three unintended changes.
Keep the clinical identifiers readable without colour. “Left forearm” and “right shin” should survive a black-and-white print, a phone image and a verbal explanation. A coloured dot can assist recognition but should not be the only link to a tube. When the actual dispensed product becomes available, match its verified name, strength and formulation to the relevant row; a training letter cannot serve as the medicine identifier on a real prescription.
On a narrow screen, scroll the table horizontally to read all columns.
| Product and site | Relationship | 28 October change | What the replacement copy must preserve |
|---|---|---|---|
| E cream — left forearm | E-L | Unchanged | Its own amount, timing and review condition from the signed plan |
| E cream — right shin | E-R | Unchanged | The separate site row; do not infer its instructions from E-L |
| S ointment — left forearm | S-L | End/review condition changed by the doctor | The revised condition applies to S-L only; other instructions remain attributable to their source |
| X cream — right shin | X-R | Unchanged | Its existing plan, without copying the S-L revision |
A pack-size check can help a clinic notice a possible mismatch between the amount prescribed and the amount supplied. It cannot determine the correct treatment or prove what the patient applied. HealthHub’s conventional adult FTU is approximately 0.5 g. Treat that as an explanatory approximation tied to its measuring method, not a calibration guarantee for every tube, product or person.
In a separate arithmetic exercise, a 30 g pack represents approximately 60 conventional FTUs if the 0.5 g assumption is used. An assumed total of 24 FTUs corresponds to approximately 12 g, leaving a theoretical 18 g from an initially full 30 g pack. These totals are invented for checking multiplication and subtraction; they are not T-18’s prescribed amount, a course length or a recommendation for any body area.
Now suppose a valid comparison of contents suggests 17 g remains. The apparent reduction is 13 g, equivalent to approximately 26 FTUs under the same assumption. It is 1 g more than the theoretical 12 g, but this does not establish over-application. The starting content, measurement uncertainty, product left in the nozzle, spillage and use at other times can affect the comparison. A partly used tube weighed with its packaging does not directly reveal grams of product remaining.
Ask about actual use before interpreting the arithmetic. A patient may have applied the product to an additional area, used another tube, misunderstood a shared instruction or had difficulty expressing the amount. Record what they describe and arrange the relevant clinical review. Do not divide pack size by an assumed daily amount and present the answer as the doctor’s intended duration.
The same caution applies when the packaging changes. A pump or differently sized nozzle should not inherit an FTU-to-pump conversion that nobody verified. The measuring explanation must match the supplied presentation. If a pharmacist proposes another formulation or device, review the implications for the instructions and demonstrate the appropriate method rather than preserving a superficially similar unit.
On a narrow screen, scroll the table horizontally to read all columns.
| Question | Calculation | Illustrative result | What the result does not establish |
|---|---|---|---|
| Approximate units in an initially full pack | 30 g ÷ 0.5 g per FTU | 60 FTUs | The appropriate amount for a patient or site |
| Content represented by an assumed total | 24 FTUs × 0.5 g per FTU | 12 g | A prescription, frequency or treatment duration |
| Theoretical content remaining | 30 g − 12 g | 18 g | A measured remainder or proof of correct application |
| Apparent reduction if contents were 17 g | 30 g − 17 g; 13 g ÷ 0.5 g per FTU | 13 g, approximately 26 FTUs | Where, when or by whom the contents were used |
| Difference from the theoretical reduction | 13 g − 12 g | 1 g | Overuse, underuse or a clinical outcome |
Return to T-18’s application map. A patient can name the left forearm correctly yet pick the wrong tube. They can also choose the correct tube and still misunderstand its amount or review condition. Ask for one demonstration at a time: identify the product, indicate the site, describe the measuring method and explain when the instruction changes or needs review. A single “understood” checkbox hides which part was actually checked.
In this fictional encounter, the patient first links S to both sites because the older copy used a repeated “affected area” phrase. The doctor corrects the map and asks the patient to explain it again. The patient then links S to the left forearm only and identifies X for the right shin. The distinction now demonstrated is product-to-site recognition; the record must not claim that actual application technique was observed if the real products were unavailable.
The patient prefers a Punjabi spoken explanation and a written copy retaining the verified medicine names. Here the clinic has checked the explanation through conversation, not independently validated a translation service. If a caregiver will help with an inaccessible area, confirm the patient’s agreement and teach that person the relevant task. A relative who collected the prescription may still need a separate explanation before taking responsibility for application.
The filled record keeps the change, the demonstration and its limits together. It also records that the actual supplied packs have not yet been compared with the prescription. The clinic can arrange the agreed check through an appropriate consultation or pharmacy handover without requesting sensitive body photographs in a general appointment channel. A photograph of a tube, a body-site image and a complete clinical record have different purposes and privacy implications.
At follow-up, compare the patient’s account with each product-site row. A new symptom, an unintended site or a changed formulation deserves assessment even when the electronic instructions look correct. Conversely, a clear map and successful teach-back do not establish treatment response. Keep the observation specific enough that another clinician can see what was demonstrated and what still depends on the real-world supply and use.
At review, ask what was actually applied, to which site and for how long. A remaining tube does not establish adherence or non-adherence; pack size, area treated and the individual plan all affect how much remains. Record the patient’s account before judging why the skin condition changed.
When the clinician revises the plan, identify which product-site instruction has changed and which continues. A new prescription that lists only the changed item can leave the patient unsure about the other treatments. An updated application map should make the relationship to the earlier copy clear.
If the patient has applied a product to an unintended area or used a different formulation, arrange the relevant clinical assessment. Correcting the text is useful, but it does not establish that the previous exposure has been evaluated. Preserve the original instruction and the reported use as separate evidence.
The outline below supports the consultation and handover. It is not a dermatology treatment protocol. Complete it only with the patient-specific plan and record any question that needs a clinician or pharmacist to clarify the actual product instructions.
Prepare a fictional case with three labelled products used across two body areas under a clinician-approved test plan. Give one product a different review condition. Inspect whether the editor, printed prescription and patient summary retain the product-to-site mapping without borrowing the first row’s directions.
Change one formulation and one site-specific instruction, then compare old and new versions. The useful evidence is whether the patient can tell what changed and what remained applicable. A generic application icon or a quantity field alone cannot demonstrate that the complete plan survives printing.
Use this case to evaluate the current Bractis workflow. The article describes the evidence a clinic should inspect; it does not assert that body maps, FTU calculators or product-specific application advice are implemented or clinically validated.
A patient receives three products for two different sites, but the initial draft repeats “apply locally” on every line. The clinician replaces the generic wording with a product-to-site map, an explained measuring method and separate review conditions. At follow-up, one product changes while the others remain under the reviewed plan. The revised copy identifies the changed instruction, and the clinic records what the patient actually used rather than assuming all tubes followed the same course.
Use these prompts in your clinic’s own notes. Record the result, responsible person and next action for each item.
It defines a measuring method, not a universal treatment amount. The clinician selects the quantity for the product, patient and body area and explains how to apply that plan.
The percentage for one corticosteroid does not establish potency relative to a different corticosteroid. Verify the exact product and follow the prescriber’s site-specific plan.
It is inadequate when the patient cannot identify the intended site, product, amount, frequency or review condition, especially when several lesions or tubes are involved.
A proposed formulation change needs appropriate review. Do not assume that presentation, application advice and suitability remain identical merely because part of the medicine name matches.
Not by itself. Ask about the actual site, amount, frequency and duration, and consider the pack and treatment area before interpreting what remains.
Yes. Record each product-to-site relationship clearly when the amount, timing, exclusions or review condition differ. Keep both rows visible, and do not copy a change intended for one area into the other without the prescriber’s review.
No. Pack size and an approximate FTU conversion describe quantity, not the intended course. The prescriber’s product, site, amount, frequency and end or review plan determine the instructions. Remaining contents do not independently prove adherence.
Updated on . This article combines the cited references with Bractis’s original workflow analysis and illustrative examples. Product capabilities depend on the configured scope. No independent clinical or legal review is claimed.
UK patient guidance on product, site and strength distinctions. No universal steroid course or withdrawal schedule is reproduced.
Definition of the conventional adult fingertip unit. Used to explain measurement, not to select a patient-specific quantity.
UK product information illustrating formulation-specific instructions. No medicine or duration is recommended for an individual reader.
Prepare Hindi medicine directions with a bilingual meaning checklist, source-version tracking and a worked patient-understanding handover.
Resolve medicine shortages with a worked alternative-product comparison, line-specific approval, partial-supply arithmetic and patient handover.
Review accessible prescriptions with a worked print, phone and text-copy comparison, patient usability observations and clear version control.
Map three fictional topical products to two body areas, revise one instruction and check that the printed and patient-facing copies preserve the exact relationships.
Request a clinic demo